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● HIV therapeutic vaccine efficacy is typically assessed in analytic treatment 
interruption (ATI) protocols trial, in which antiretroviral treatments (ART) are 
interrupted over a period of time, inducing viral rebound.
● Prematurely ART resumption when viral load reach a threshold induces missing data, 
which is a follow up censoring. Additionally, data are left-censored by a limit of 
detection (LOD).
● We are interested in the use of area under the curve normalized by the time of follow 
up (nAUC) as primary endpoint of analysis in ATI studies. Without further 
adjustment/modeling, the use of nAUC with follow up censoring is biased [Bell,2014].
● Objective: We aim at developing a broad parametric statistical test to compare the 
nAUC in ATI trials.
objectives
[Bell,2014] Bell, M. L., King, M. T., & Fairclough, D. L. (2014). Bias in area under the curve for longitudinal clinical trials with 
missing patient reported outcome data: summary measures versus summary statistics. SAGE Open, 4(2), 21582440145348580
● We want to perform the following t-test 
between the two vaccine arms 𝑔1 and 𝑔2:
Method – MEM nAUC
STEP 1: Mixed Effects Model to fit available data
 
𝑯𝟎 ∶ 𝜟  𝒏𝐀𝐔𝐂𝒈𝟏−𝒈𝟐 = 𝟎
𝑯𝟏 ∶ 𝜟  𝒏𝐀𝐔𝐂𝒈𝟏−𝒈𝟐 ≠ 𝟎
● 𝜟  𝒏𝐀𝐔𝐂𝒈𝟏−𝒈𝟐 , is calculated using a 2 steps approach using modeling:
Let 𝑌𝑖𝑗,𝑔𝑖 be the HIV RNA load 
measurement of the subject 𝑖, 
belonging to the vaccine arm 
𝑔𝑖, at the 𝑗th time point
STEP 2: Estimation of ∆𝑛AUC (Trapezoid method)
𝜟  𝒏𝐀𝐔𝐂𝒈𝟏/𝒈𝟐 =
 𝒏𝐀𝐔𝐂𝒈𝟐 −
 𝒏𝐀𝐔𝐂𝒈𝟏 = 𝓕𝒈𝟏/𝒈𝟐  𝛾0,
 𝛽𝑘
𝑔1 , 𝑡𝑔1 ,
 𝛽𝑘
𝑔2 , 𝑡𝑔2



















(𝑡𝑗−1,𝑔) 𝑡𝑗,𝑔 = 
𝑖∈𝑔





















Population dynamics = Fixed effects Random Effects
Splines Curves, Group-specific
● We simulated trials of 2 vaccine arms with 20, 50 or 100 patients by group
● Protocol defining ATI:
o 24 weeks of ART interruption
o 1 measure every week
● 3 values of Δ𝑛AUC tested:
∆𝑛AUC ∈ 0,−0.1, −0.25 log10cp/ml
Simulations
Different profiles 
between the 2 groups
Same profiles between
the 2 groups
*𝛼: Threshold of lost of follow up ; 𝑌𝑖𝑗,𝑔 ∈  𝑌𝑖𝑗,𝑔 ∃𝑗







∆𝑛AUC = −0.25LOD = 50 cp/ml
o ART resumption above 𝛼∗(+ 1 confirmed measure)
1. α = 100 000 cp/ml           5-40 % of censored follow up
2. α = 50 000 cp/ml            30-80 % of censored follow up
3. α = 10 000 cp/ml            95-100 % of censored follow up
Unbalanced missing data












-0.1 -0.25 -0.1 -0.25
No censoring
Raw data* 0,060 0,95 1,00 0,046 0,94 1,00
MEM nAUC 0,058 0,96 1,00 0,049 0,95 1,00
LOD
Raw data 0,056 0,96 1,00 0,047 0,94 1,00
MEM nAUC 0,060 0,95 1,00 0,047 0,94 1,00
LOD & 
𝜶 = 𝟏𝟎𝟎 𝟎𝟎𝟎
Raw data 0,060 0,49 1,00 0,540 0,92 1,00
LOCF 0,052 0,84 1,00 0,281 0,31 1,00
Mean Imput. 0,059 0,51 1,00 0,529 0,83 1,00
MEM nAUC 0,063 0,94 1,00 0,053 0,92 1,00
LOD & 
𝜶 = 𝟓𝟎 𝟎𝟎𝟎
Raw data 0,050 0,05 0,13 0,946 0,20 0,70
LOCF 0,046 0,77 1,00 0,483 0,11 1,00
Mean Imput. 0,051 0,05 0,14 0,940 0,81 0,70
MEM nAUC 0,063 0,84 1,00 0,045 0,77 1,00
LOD & 
𝜶 = 𝟏𝟎 𝟎𝟎𝟎
Raw data 0,041 0,04 0,12 0,894 0,91 0,85
LOCF 0,058 0,20 0,81 0,555 0,18 0,13
Mean Imput. 0,039 0,04 1,00 0,746 0,83 0,80
MEM nAUC 0,330 0,32 0,30 0,624 0,58 0,37
*Methods using common t-test applied on mean nAUC estimated with individual trajectories: 
1. Raw data: Data without any transformation ; 2. LOCF: Last Observation Carried Forward ; 3. Mean Imputation 
N= 50 patients/group
 No censoring & LOD :
All methods are valid
 LOD & α=100 000 and 50 000:
 MEM nAUC method valid for all profiles
 Indiviual methods failed at least for 
profile 2
 LOD & α=10 000:
χ All methods failed for at least one profile
Valid results
Weak power
Too high Type-I Error or too weak power
Meaningless with wrong Type-I Error
Application of the method on Real data
Method Estimate (SE) 95% CI P-value
Data -0.346 (0.170) [-0.680 ; -0.013] 0.046
LOCF -0.380 (0.198) [-0.770 ; 0.007] 0.060
Mean Imput. -0.345 (0.312) [-0.957 ; 0.266] 0.276
MEM nAUC -0.454 (0.214) [-0.874 ; -0.034] 0.034
Method Estimate (SE) 95% CI P-value
Data -0.030 (0.175) [-0.312 ; 0.372] 0.864
LOCF -0.018 (0.186) [-0.382 ; 0.346] 0.924
Mean Imput. 0.217 (0.245) [-0.263 ; 0.697] 0.959
MEM nAUC 0.078 (0.214) [-0.342 ; 0.498] 0.715
No significant difference of nAUC between the 
2 groups of treatment
Significant difference of nAUC between the 2 groups 
of treatment
LIGHT* – Observed data
Vaccine: 59 patients Control: 32 patients
Vac-IL2** – Observed data
Vaccine: 34 patients Control: 37 patients
*VRI02 ANRS 149 LIGHT (NCT01492985)
Palich, R. et al (2019). Viral rebound in semen after antiretroviral treatment 
interruption in an HIV therapeutic vaccine double-blind trial. Aids, 33(2), 279-284.
**ANRS 093 Vac-IL2 (NCT00196651)
Lévy, Y. et al (2005). Immunological and virological efficacy of a therapeutic immunization 
combined with interleukin-2 in chronically HIV-1 infected patients. Aids, 19(3), 279-286.
● We developed and showed good properties of a parametric statistical test 
comparing nAUC of two vaccine arms in ATI trials using mixed effects spline models.
● We showed the superiority of this method to account for follow up censoring, 
especially when there is a lag in viral rebound between groups (Profile 2).
● All methods fail when there is a high percentage of follow up censoring (>90%), this 
is for example the case when the threshold of ART resumption is low (α ≤ 10 000 
copies/ml).
● The application of the method on data from HIV ATI trials allowed to show the 
superiority of experimental arm of VAC-IL2 vaccine compared to placebo, where 
other methods would have failed.
● Preprint and R-Code are available on request. 
Conclusion
